VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
WGS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
WGSGeneDx Holdings Corp.
$47.29$1.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
WGS logo

GeneDx Holdings Corp.

WGS
NASDAQ · Diagnostics & Lab Testing
$47.29
At close - Nov 17, 4:00 PM EST - USD
Market Cap$1.41B
P/E-12.7x
52W High$170.87
Volume1.99M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Revenue Scaling Offset by Persistent Losses and Cash Burn

GeneDx Holdings has grown revenue from $70.5M in Q2 2024 to $123.1M in Q3 2026 and lifted gross margin to roughly 69.9%, which suggests the genetic testing platform has real demand and pricing traction.

GrowthExpanding
ProfitabilityStrained
ValuationExpensive
TechnicalsWeak
Explore valuation models
MARKET ACTION

WGS price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

11/12 Beats

EPS beat 11 of last 12 quarters

02

Valuation risk

-137% Peers

P/E is 137% below peer median

03

Market leadership

RS 23 · Lag

Laggard (Underperforming 77% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 9

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
WGS-64.26%
S&P 500 (^GSPC)+7.21%
1-Year Return
WGS-63.50%
S&P 500 (^GSPC)+10.03%
3-Year Return
WGS+2855.63%
S&P 500 (^GSPC)+1.67%
5-Year Return
WGS-79.73%
S&P 500 (^GSPC)+51.79%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-12.7x
Forward P/E
472.9x
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-12.7x
N/A
N/A
EV/EBITDA
N/A
261.2x
N/A
Price/FCF
N/A
245.2x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$17.34-63.3%
Base (Fair)$27.88-46.8%
Bull$29.26-38.1%
$17.34 Bear$27.88 Base$29.26 Bull
Current Market Price: $47.29
Trades at a 69.6% premium to Base DCF ($27.88)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$428M+40.0% YoY
Net income FY25
-$21M+59.8% YoY
Free cash flow FY25
$14M+142.0% YoY
Operating margin FY25
-2.8%+4.8 pts YoY
ROIC (FY25)-3%
Avg ROIC 5Y-134.8%
ROE (TTM)-42.3%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate11/12 (92%)
Revenue Beat Rate9/12 (75%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 9, 2026
$0.28+284.3%
vs $0.07
$123M+0.1%
vs $123M
Q3 2026
Aug 3, 2026
$0.01+105.3%
vs -$0.19
$114M+3.1%
vs $111M
Q2 2026
May 4, 2026
-$0.28-366.7%
vs -$0.06
$102M-9.1%
vs $112M
Q1 2026
Feb 23, 2026
$0.14+27.3%
vs $0.11
$121M+0.6%
vs $120M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Business Wire·6d ago
GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx to Participate in Upcoming Investor Conferences.

The Motley Fool·Nov 10, 2026
Why GeneDx Holdings Stock Just Dropped 16.6%

GeneDx lowered its 2026 exome and genome volume growth target to at least 28% after third-quarter testing volume fell short of expectations. Sales rose 5% to $123.1 million, in line with estimates, but the 32,134 exome and genome results were up 25% against the 29.2% or more the company had promised.

Schaeffers Research·Nov 10, 2026
4 Post-Earnings Losers Drawing Unusual Options Volume

Several stocks are seeing unusual options activity following their latest earnings reports, with Hims & Hers Health Inc (NYSE:HIMS), GeneDx Holdings Corp (NASDAQ:WGS), Groupon Inc (NASDAQ:GRPN), and Digital Turbine Inc (NASDAQ:APPS) all suffering double-digit losses today.

Business Wire·Nov 10, 2026
GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Research Demonstrates Medical Actionability of Exome and Genome Sequencing Results in Large Real-World Study of More Than 300,000 Patients.

Filtered for GeneDx Holdings Corp.More Headlines
04

Compare before deciding

Benchmark WGS against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for GeneDx Holdings Corp. (WGS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
WGS logoWGSGeneDx Holdings Corp.Current
$47.29$1.41B-12.7239.97%-24.1%-42.26%—
PACB logoPACBPacific Biosciences of California, Inc.
$1.82$565.3M-4.323.89%-81.31%-2618.51%—
NTRA logoNTRANatera, Inc.
$287.47$41.17B-251.4435.9%-5.66%-9.18%—
CDNA logoCDNACareDx, Inc
$74.56$3.85B31.8713.79%25.86%34.08%—
ILMN logoILMNIllumina, Inc.
$202.61$30.65B34.86-0.78%19.72%31.45%—
BFLY logoBFLYButterfly Network, Inc.
$5.75$1.53B-28.5418.96%-43.56%-28.22%—

Compare WGS vs Peers

GeneDx Holdings Corp. (WGS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PACB

Most directly comparable listed peer for WGS.

Scale Benchmark

vs TMO

Larger-name benchmark to compare WGS against a more recognizable public peer.

Peer Set

Compare Top 5

vs PACB, NTRA, CDNA, ILMN

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

WGS SEC Filings & Documents

GeneDx Holdings Corp. (WGS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 9, 2026·SEC

Material company update

Aug 3, 2026·SEC

Material company update

Jun 23, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 23, 2026·SEC

FY 2025

Feb 20, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 9, 2026·SEC

FY 2026

Aug 3, 2026·SEC

FY 2026

May 4, 2026·SEC

Get notified when WGS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

WGS Frequently Asked Questions

GeneDx Holdings Corp. (WGS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is GeneDx Holdings Corp.'s revenue?

GeneDx Holdings Corp. (WGS) reported $460.8M in revenue over the trailing twelve months. Revenue was $427.5M in fiscal year 2025. That is 138% more than the $179.3M of fiscal year 2020.

How fast is GeneDx Holdings Corp. growing?

GeneDx Holdings Corp. (WGS) grew revenue by 14.6% over the trailing twelve months, compared with the twelve months before.

Is WGS profitable?

No. GeneDx Holdings Corp. (WGS) reported a net loss of $111.0M over the trailing twelve months.

Dividend & Returns
What is WGS's return on equity?

GeneDx Holdings Corp. (WGS) had a return on equity (ROE) of -42.3% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is GeneDx Holdings Corp.'s free cash flow?

GeneDx Holdings Corp. (WGS) had negative free cash flow of $101.2M over the trailing twelve months.

What if you invested $1,000 in WGS back in 2020?

Total return calculator · dividends reinvested · 6+ years of data

See returns →